<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03889496</url>
  </required_header>
  <id_info>
    <org_study_id>NL47132.091.14</org_study_id>
    <nct_id>NCT03889496</nct_id>
  </id_info>
  <brief_title>Quantitative GLP-1 Receptor Imaging Correlated to ex Vivo Distribution of In-111-exendin</brief_title>
  <acronym>GLP1-ex-vivo</acronym>
  <official_title>Quantitative GLP-1 Receptor Imaging Correlated to ex Vivo Distribution of In-111-exendin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal is to study the correlation of pancreatic uptake of In-111-DTPA-exendin-4
      (measured by ex vivo counting) with the beta cell mass determined in the pancreatic specimens
      obtained after surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to fully characterize the highly promising tracer In-111-DTPA-exendin-4 in humans,
      quantitative SPECT imaging will be correlated to the ex vivo tracer distribution in patients
      undergoing pancreatectomy or a Whipple procedure. In vivo imaging will be combined with
      post-pancreatectomy (micro)autoradiography, measurement of In-111-DTPA-exendin-4
      concentrations in the pancreas using a gamma counter and morphometric determination of the
      actual beta cell mass. By this means, the relation between tracer uptake and beta cell mass
      in non-diabetic patients and T2D patients will be established. These highly relevant data
      will allow the improvement of the interpretation of clinical quantitative SPECT data in
      subsequent studies in patients with T1D and T2D. In addition, high uptake has been observed
      in the duodenum/pyloric area in patients in an ongoing study. At this point in time, it
      remains unclear which cells are responsible for this uptake. It would be of great interest to
      identify the GLP-1R positive cells in order to better understand the physiological actions of
      GLP-1 agonists.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2015</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between the tracer uptake (counts) and beta cell mass (mg)</measure>
    <time_frame>4 years</time_frame>
    <description>The primary objective is the correlation between the ex vivo In-111-exendin tracer accumulation in the pancreas (counts) of patients undergoing pancreatectomy or Whipple procedure, and the beta cell mass (mg) in non- diabetic patients and patients with diabetes.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Scheduled for (partial) pancreatectomy or Whipple procedure</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>I.v. injection with In-111-DTPA-exendin-4 and SPECT/CT scan</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>indium-111-exendin SPECT/CT</intervention_name>
    <description>SPECT/CT imaging after injection with In-111-DTPA-exendin-4</description>
    <arm_group_label>Scheduled for (partial) pancreatectomy or Whipple procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled for partial or complete pancreatectomy or Whipple procedure at Radboudumc

        Exclusion Criteria:

          -  Resection that provides insufficient amount of tissue

          -  Previous treatment with synthetic Exendin (Exenatide, ByettaÂ®) or Dipeptidyl-
             Peptidase IV inhibitors

          -  Breast feeding

          -  Pregnancy or the wish to become pregnant within 6 months

          -  Renal disease

          -  Liver disease

          -  Age &lt; 18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Gotthardt, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tom Jansen, MSc</last_name>
    <phone>0031243667244</phone>
    <email>tom.jp.jansen@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Gotthardt, Prof. Dr.</last_name>
    <phone>0031243619061</phone>
    <email>martin.gotthardt@radboudumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Radboud university medical center</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom Jansen, MSc</last_name>
      <phone>00312467244</phone>
      <email>tom.jp.jansen@radboudumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Marti Boss, MSc</last_name>
      <phone>0031243619097</phone>
      <email>Marti.Boss@radboudumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Gotthardt, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marti Boss, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tom Jansen, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 23, 2019</study_first_submitted>
  <study_first_submitted_qc>March 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2019</study_first_posted>
  <last_update_submitted>April 4, 2019</last_update_submitted>
  <last_update_submitted_qc>April 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>exendin-4</keyword>
  <keyword>GLP-1 receptor imaging</keyword>
  <keyword>SPECT</keyword>
  <keyword>pancreas</keyword>
  <keyword>surgery</keyword>
  <keyword>quantification</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

